T1	PROC 46 74	Estudio de extensión abierto
T2	Date 95 108	a largo plazo
T3	CHEM 112 134	treprostinil palmitilo
T4	LIVB 163 172	pacientes
#1	AnnotatorNotes T4	C0030705; Patients; Patient or Disabled Group
T5	DISO 177 207	hipertensión arterial pulmonar
#2	AnnotatorNotes T5	C2973725; Pulmonary arterial hypertension; Disease or Syndrome
T6	PROC 230 258	Estudio de extensión abierto
T7	PROC 264 310	evaluar la seguridad, tolerabilidad y eficacia
T8	Date 319 332	a largo plazo
T9	CHEM 336 358	treprostinil palmitilo
T10	LIVB 387 396	pacientes
#3	AnnotatorNotes T10	C0030705; Patients; Patient or Disabled Group
T11	DISO 401 431	hipertensión arterial pulmonar
#4	AnnotatorNotes T11	C2973725; Pulmonary arterial hypertension; Disease or Syndrome
T12	LIVB 455 468	Participantes
T13	ANAT 503 527	arterias de los pulmones
T14	LIVB 554 567	Participantes
T15	DISO 572 602	hipertensión arterial pulmonar
#5	AnnotatorNotes T15	C2973725; Pulmonary arterial hypertension; Disease or Syndrome
T16	LIVB 632 645	Participantes
T17	PROC 665 671	visita
T18	PROC 682 693	tratamiento
#6	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	CHEM 777 781	TPPI
T20	DISO 790 793	HAP
#7	AnnotatorNotes T20	C2973725; Pulmonary arterial hypertension; Disease or Syndrome
T21	LIVB 799 812	participantes
T22	Neg_cue 841 843	no
T23	Negated 851 861	disponible
T24	Date 903 915	preinclusión
T25	Duration 958 964	un año
T26	PROC 971 977	visita
T27	PROC 988 999	tratamiento
#8	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	Date 1015 1027	preinclusión
T29	PROC 1033 1058	Evaluaciones de selección
T30	Duration 1145 1159	más de 30 días
T31	PROC 1169 1175	visita
T32	Date 1269 1281	preinclusión
T33	CHEM 1286 1290	TPPI
T34	DISO 1299 1302	HAP
#9	AnnotatorNotes T34	C2973725; Pulmonary arterial hypertension; Disease or Syndrome
T35	PROC 1328 1352	consentimiento informado
#10	AnnotatorNotes T35	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T36	LIVB 1391 1404	Participantes
T37	DISO 1434 1451	hipersensibilidad
#11	AnnotatorNotes T37	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T38	DISO 1454 1485	reacción adversa al medicamento
T39	CHEM 1560 1564	TPPI
T40	DISO 1573 1576	HAP
#12	AnnotatorNotes T40	C2973725; Pulmonary arterial hypertension; Disease or Syndrome
T41	LIVB 1601 1613	investigador
#13	AnnotatorNotes T41	C0035173; Research Personnel; Professional or Occupational Group
T42	Spec_cue 1615 1621	podría
T43	PROC 1634 1658	continuar el tratamiento
T44	CHEM 1663 1667	TPPI
T45	Spec_cue 1668 1673	puede
T46	LIVB 1714 1726	participante
T47	PROC 1744 1769	administración parenteral
T48	Route 1759 1769	parenteral
T49	CHEM 1773 1798	análogos de prostaciclina
T50	CHEM 1813 1816	TRE
T51	CHEM 1818 1830	epoprostenol
#14	AnnotatorNotes T51	C0033567; epoprostenol; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T52	CHEM 1915 1919	TPPI
T53	CHEM 1945 1970	análogos de prostaciclina
T54	Route 1971 1980	inhalados
T55	CHEM 1995 1998	TRE
#15	AnnotatorNotes T55	C0014935; Estrogen Replacement Therapy; Therapeutic or Preventive Procedure
T56	CHEM 2000 2006	Tyvaso
T57	CHEM 2011 2019	iloprost
#16	AnnotatorNotes T57	C0079594; iloprost; Organic Chemical · Pharmacologic Substance
T58	CHEM 2023 2055	análogos orales de prostaciclina
T59	Route 2032 2038	orales
T60	CHEM 2070 2073	TRE
#17	AnnotatorNotes T60	C0014935; Estrogen Replacement Therapy; Therapeutic or Preventive Procedure
T61	CHEM 2075 2084	Orenitram
T62	CHEM 2090 2112	agonistas del receptor
T63	CHEM 2127 2136	selexipag
#18	AnnotatorNotes T63	C2000145; selexipag; Organic Chemical · Pharmacologic Substance
T64	Duration 2154 2162	24 horas
T65	PROC 2186 2212	administración del fármaco
T66	PHYS 2229 2237	Embarazo
#19	AnnotatorNotes T66	C0032961; Pregnancy; Organism Function
T67	PHYS 2240 2249	lactancia
#20	AnnotatorNotes T67	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T68	DISO 2264 2293	afección médica o psicológica
T69	LIVB 2381 2393	investigador
#21	AnnotatorNotes T69	C0035173; Research Personnel; Professional or Occupational Group
T70	DISO 2407 2417	enfermedad
#22	AnnotatorNotes T70	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T71	Spec_cue 2458 2463	pueda
T72	Speculated 2477 2495	riesgo irrazonable
T73	LIVB 2504 2516	participante
T74	Form 362 367	polvo
T75	Route 373 383	inhalación
T76	Form 138 143	polvo
T77	Route 149 159	inhalación
T78	DISO 473 495	tension sanguínea alta
T79	Date 761 773	preinclusión
T80	DISO 2309 2333	anomalías de laboratorio
T81	Speculated 1687 1705	riesgo irrazonable
T82	CONC 675 693	fin de tratamiento
T83	Quantifier_or_Qualifier 851 861	disponible
T84	Observation 879 915	completar el estudio de preinclusión
T85	Observation 920 946	elegibles para inscribirse
T86	CONC 981 999	fin de tratamiento
T87	Quantifier_or_Qualifier 1069 1078	completas
T88	Observation 1096 1124	elegibilidad para participar
T89	CONC 1176 1178	de
T90	CONC 1179 1193	fin de estudio
T91	Observation 1308 1317	Capacidad
T92	Quantifier_or_Qualifier 1520 1535	anticipadamente
T93	Observation 1687 1693	riesgo
T94	CONC 1921 1931	Se permite
T95	CONC 1935 1941	inicio
T96	Observation 2309 2333	anomalías de laboratorio
T97	Quantifier_or_Qualifier 2334 2344	relevantes
T98	Quantifier_or_Qualifier 2418 2423	nueva
T99	Quantifier_or_Qualifier 2426 2453	insuficientemente entendida
T100	Observation 2477 2483	riesgo
T101	Quantifier_or_Qualifier 2484 2495	irrazonable
T102	Observation 2550 2577	participación en el estudio
T103	Patient 163 172	pacientes
T104	Patient 387 396	pacientes
T105	Patient 455 468	Participantes
T106	Patient 554 567	Participantes
T107	Patient 632 645	Participantes
T108	Patient 799 812	participantes
T109	Future 935 946	inscribirse
T110	History_of 1258 1265	estudio
T111	Patient 1391 1404	Participantes
T112	History_of 1434 1451	hipersensibilidad
T113	History_of 1454 1470	reacción adversa
T114	History_of 1560 1564	TPPI
T115	Other 1601 1613	investigador
T116	Patient 1714 1726	participante
T117	History_of 1995 1998	TRE
T118	History_of 2000 2006	Tyvaso
T119	Other 2381 2393	investigador
T120	Patient 2504 2516	participante
